Pancreatic Cancer Metastatic Clinical Trial
Official title:
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine Versus Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Verified date | March 2024 |
Source | RenJi Hospital |
Contact | Liwei Wang, Doctor |
Phone | +86 16621086648 |
lwwang[@]163.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Aim:Evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. Drug information: - anti-PD1 antibody (Camrelizumab) - AG regimens:the standard first-line regimens for metastatic pancreatic cancer.
Status | Recruiting |
Enrollment | 401 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Aged >= 18 years, male or female; 2. Histologically or Cytologically confirmed metastatic pancreatic adenocarcinoma; 3. Patients have never received systematical anti-cancer therapy; 4. Based on Response Evaluation Criteria In Solid Tumors (RECIST1.1), there should be at least one measurable lesion which has never received local treatment like radiotherapy(The lesion located in previous radiotherapy areas can also be selected as target lesions if the progress confirmed.) 5. ECOG:0-1; 6. Expected survival>=12 weeks; 7. Essential organs function must meet the following criteria (Any blood products, growth factor, leucocyte promoting drugs, platelet promoting drugs, drugs for anemia are not allowed in 14 days before the first use of the experimental medication): 1. Absolute neutrophil count(ANC) >= 1.5x10^9/L 2. Platelet >= 85x10^9/L 3. Hemoglobin >= 90g/L 4. Serum Albumin >= 30g/L 5. Total bilirubin <= 2.0 ULN (Biliary obstructive patients after biliary drainage <= 2.5 ULN), AST and ALT <= 3.0 ULN (patients with liver metastasis <= 5 ULN); 6. Creatinine clearance rate >60 mL/min; 7. Activated Partial Thromboplastin Time and International Standardized Ratio <= 1.5 ULN (Patients using stable dose of anticoagulant therapy such as low molecular weight heparin or warfarin and INR is within the expected range of anticoagulants can be selected.) Exclusion Criteria: - 1. Patients with central nervous system metastasis. 2. Patients only have local advanced diseases. 3. Patients have uncontrolled pleural, pericardial or abdominal effusion requiring drainage. 4. Patients with history of allergy to monoclonal antibodies, any component of SHR-1210, paclitaxel(Albumin Bound) and Gemcitabine. 5. Patients have ever received anti PD-1 or anti PD-L1 therapy in the past. 6. Patients have accepted any experimental medication.within 4 weeks before the first dose of our experimental medication administration. 7. Patients are enrolled in another clinical trial except for observational clinical trial (Non-interventional) or the follow-up of the interventional clinical trial. 8. Patients accepted the last dose of anti-cancer therapy (including radiotherapy) within 4 weeks before the first dose of experimental medication administration. 9. Patients who need corticosteroid or other immunosuppressive agents. 10. Patients who ever received anti-cancer vaccine or have received live vaccine within 4 weeks before the first dose of administration. 11. Patients who have received major surgery within 4 weeks before the first dose of administration. 12. Patients with active autoimmune diseases, history of autoimmune diseases. 13. History of immunodeficiency, including HIV positive test, or other acquired, congenital immunodeficiency disorders, or history of organ transplantation and allogeneic bone marrow transplantation. 14. Patients with uncontrolled cardiovascular clinical symptoms or diseases. 15. Severe infections occurred within 4 weeks before the first administration. 16. History of interstitial lung disease and non- infectious pneumonia. 17. Patients with active pulmonary tuberculosis (APTB) infection confirmed by medical history or CT examination. 18. Patients with active hepatitis B or hepatitis C. 19. Patients with any other malignant tumors diagnosed within 5 years before the first administration. 20. Pregnant or lactating women. 21. According to the researchers, participants have other factors that may force them to end up the study. |
Country | Name | City | State |
---|---|---|---|
China | Changhai Hospital | Shanghai | Shanghai |
China | Renji hospital | Shanghai | Shanghai |
China | Ruijin hospital | Shanghai | Shanghai |
China | Shanghai Cancer Center | Shanghai | Shanghai |
China | Shanghai General Hospital | Shanghai | Shanghai |
China | Zhongshan Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | CA19-9 in serum | CA19-9 in serum | 3 years | |
Primary | Progress free survival | Time until progress free since randomized. | 3 years | |
Secondary | Objective Response Rate | Rate of participants with complete response and partial response. | 3 years | |
Secondary | Disease Control Rate | Rate of participants with complete response and partial response and stable disease. | 3 years | |
Secondary | Duration of Response | Time until progress(PD) since first evaluation as CR or PR. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06155136 -
RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
|
||
Not yet recruiting |
NCT05047991 -
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04469556 -
Pancreatic Adenocarcinoma Signature Stratification for Treatment
|
Phase 2 | |
Completed |
NCT03504423 -
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
|
Phase 3 | |
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04799431 -
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
|
Phase 1 | |
Completed |
NCT03412799 -
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
|
Phase 1 | |
Withdrawn |
NCT04852367 -
PanDox: Targeted Doxorubicin in Pancreatic Tumours
|
Phase 1 | |
Recruiting |
NCT04467593 -
Safety Study of Whole Body Hyperthermia for Advanced Cancer
|
N/A | |
Recruiting |
NCT02959151 -
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
|
Phase 1/Phase 2 | |
Completed |
NCT01652976 -
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
Completed |
NCT04721301 -
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
|
Phase 1 | |
Recruiting |
NCT04667403 -
Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer
|
N/A | |
Recruiting |
NCT06168812 -
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06076837 -
The Seven Trial: Exploiting the Unfolded Protein Response
|
Phase 1 | |
Active, not recruiting |
NCT03984214 -
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05254171 -
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04116073 -
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
|
Phase 2 | |
Recruiting |
NCT04338763 -
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT06030622 -
Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
|
Phase 1/Phase 2 |